Navigation Links
Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Date:7/21/2008

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) has rescheduled the time of its conference call and webcast to review the sales and earnings results for the 2008 second quarter to approximately 4:45 p.m. (EDT) from 8 a.m. today. The quarterly financial results will be issued today, July 21, 2008, after the close of the New York Stock Exchange.

Schering-Plough made the second-quarter earnings schedule change because Terje Pedersen, M.D., Ph.D., Chief, Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, and the primary investigator of Simvastatin plus Ezetimibe in Aortic Stenosis study (SEAS), has announced that he will present an update on the study at 1 p.m. (U.S. EDT) today.

To listen live to the Schering-Plough second quarter earnings conference call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #50992673. A replay of the call will be available beginning later on July 21 through 5 p.m. on July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #50992673. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 20.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
4. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
5. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
6. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
7. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
8. Schering-Plough CEO Buys $2 Million in Common Shares
9. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
10. Schering-Plough Reports Financial Results for First Quarter of 2008
11. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
(Date:11/30/2016)...  Tempus, a technology company focused on supporting ... Cancer Center have partnered to better determine which ... treatment based on next generation genomic and transcriptomic ... research collaboration, Tempus will provide sequencing and analysis ... to Penn. Utilizing next-generation sequencing, machine learning and ...
(Date:11/30/2016)... 30. November 2016   Merck , ... die Unterzeichnung einer Reihe von Vereinbarungen mit ... Evotec AG Screeningleistungen für Mercks Palette genetischer ... Zugriff auf diese Bibliotheken in Kombination mit ... schnelleren Weg zur Ermittlung und Erforschung neuer ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):